Thorax
-
Comparative Study Clinical Trial Controlled Clinical Trial
Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.
BACKGROUND Preliminary evidence suggests that regular inhalation of nebulised amiloride reduces sputum viscoelasticity, increases the clearance of sputum by mucociliary mechanisms and by coughing and reduces the rate of deterioration in lung function in patients with cystic fibrosis. These effects depend on adequate delivery of amiloride to the airways. This study was performed to quantify and compare pulmonary deposition of amiloride produced by two different nebuliser systems. ⋯ Pulmonary deposition was completed more rapidly with the Fisoneb (4-5 minutes) than with the System 22 nebuliser (7-8 minutes) and the Fisoneb was preferred by the patients. CONCLUSIONS Both nebulisers appeared to deliver adequate amounts of amiloride to the lungs, but treatment with the Fisoneb nebuliser was quicker, more efficient, and more acceptable to the patients. Of the two nebulisers assessed, the Fisoneb would be preferred for clinical trials.
-
A case of exogenous lipoid pneumonia was documented by computed tomography and magnetic resonance imaging. Although strongly suggesting the presence of fat on T1 weighted images, magnetic resonance does not produce images specific for this condition. Computed tomography is the best imaging modality for its diagnosis.